drugset
drugset / Trial / NCT03130439

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

NCT03130439 ↗

Phase 2 Terminated 27 enrolled Dana-Farber Cancer Institute Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

Timeline

Start
2017-05-26
Primary completion
2021-08-18
Completion
2022-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule — Oral

Indications

breast cancer